News Novo Nordisk teams up with NVIDIA on AI models Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.
News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.
News MHRA advises contraception for women taking 'skinny jabs' Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.
News Novo Nordisk's dropping share price spells the end for CEO Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.
News Novo makes fresh obesity play with $2.2bn Septerna deal A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
